Category : Probiotics

The identification of an isolate at the strain level has been considered an essential requirement for any microbe that is intended to be commercialized as a probiotic. Strain-level identity is essential for both safety and efficacy evaluations. It enables traceability in laboratory tests, clinical trials and throughout the production and commercialization process. Although the health benefits of probiotics have been…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

The identification of an isolate at the strain level has been considered an essential requirement for any microbe that is intended to be commercialized as a probiotic. Strain-level identity is essential for both safety and efficacy evaluations. It enables traceability in laboratory tests, clinical trials and throughout the production and commercialization process. Although the health benefits of probiotics have been…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

The Gut Microbiota for Health publishing team is delighted to share the second summary document on the latest scientific work related to gut microbiota and probiotics! With gastrointestinal (GI) symptoms high in prevalence throughout the world, and with limited available therapeutic options for addressing functional GI disorders, is there a role for probiotics? This document covers human research that elucidates…

GMFH Editing Team
GMFH Editing Team

The Gut Microbiota for Health publishing team is delighted to share the second summary document on the latest scientific work related to gut microbiota and probiotics! With gastrointestinal (GI) symptoms high in prevalence throughout the world, and with limited available therapeutic options for addressing functional GI disorders, is there a role for probiotics? This document covers human research that elucidates…

GMFH Editing Team
GMFH Editing Team
Canadian Obesity Network

Although plenty of research in both animal models and humans during the last decade has explored the relationship between the gut microbiota and obesity and related metabolic disorders, the clinically relevant contribution of gut microbiota to obesity and related metabolic disorders is still unknown. The relationship between obesity and metabolic diseases has been recently covered in a review article by…

GMFH Editing Team
GMFH Editing Team

Canadian Obesity Network

Although plenty of research in both animal models and humans during the last decade has explored the relationship between the gut microbiota and obesity and related metabolic disorders, the clinically relevant contribution of gut microbiota to obesity and related metabolic disorders is still unknown. The relationship between obesity and metabolic diseases has been recently covered in a review article by…

GMFH Editing Team
GMFH Editing Team

Many questions arise when it comes to probiotics and gut microbiota. By what mechanisms of action can probiotics affect host health? What is the role of probiotics in preventing healthcare-associated infections? Do probiotics affect the intestinal barrier? The Gut Microbiota for Health publishing team has asked a selection of world-leading experts to weigh in on the answers, and we're pleased…

GMFH Editing Team
GMFH Editing Team

Many questions arise when it comes to probiotics and gut microbiota. By what mechanisms of action can probiotics affect host health? What is the role of probiotics in preventing healthcare-associated infections? Do probiotics affect the intestinal barrier? The Gut Microbiota for Health publishing team has asked a selection of world-leading experts to weigh in on the answers, and we're pleased…

GMFH Editing Team
GMFH Editing Team

Previous evidence from both mouse models and humans has suggested that manipulation of the gut microbiota could help us understand how to deal with the current global obesity epidemic. However, whether the effects of targeting the gut microbiota are due to improved health status in people with overweight or obesity or the result of changes in their gut microbiota composition…

Paul Enck
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.

Previous evidence from both mouse models and humans has suggested that manipulation of the gut microbiota could help us understand how to deal with the current global obesity epidemic. However, whether the effects of targeting the gut microbiota are due to improved health status in people with overweight or obesity or the result of changes in their gut microbiota composition…

Paul Enck
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.

Sepsis is a life-threatening condition characterized by systemic inflammation; it is one of the major contributors to neonatal mortality, especially in developing countries. The World Health Organization (WHO) estimates that 1 million deaths per year (10% of all under-five mortality) are due to neonatal sepsis and that 42% of these deaths occur in the first week of life. Although exclusive…

Paul Enck
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.

Sepsis is a life-threatening condition characterized by systemic inflammation; it is one of the major contributors to neonatal mortality, especially in developing countries. The World Health Organization (WHO) estimates that 1 million deaths per year (10% of all under-five mortality) are due to neonatal sepsis and that 42% of these deaths occur in the first week of life. Although exclusive…

Paul Enck
Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.

Gut Microbiota for Health is pleased to announce its participation at the 21st International Congress of Nutrition (ICN).  Organized by the International Union of Nutritional Sciences (IUNS) with the theme “From Sciences to Nutrition Security”, the event will take place at the Hotel Sheraton, Buenos Aires (Argentina) from October 15th to 20th, 2017. IUNS promotes advancement in nutrition science, research,…

GMFH Editing Team
GMFH Editing Team

Gut Microbiota for Health is pleased to announce its participation at the 21st International Congress of Nutrition (ICN).  Organized by the International Union of Nutritional Sciences (IUNS) with the theme “From Sciences to Nutrition Security”, the event will take place at the Hotel Sheraton, Buenos Aires (Argentina) from October 15th to 20th, 2017. IUNS promotes advancement in nutrition science, research,…

GMFH Editing Team
GMFH Editing Team

The 10th European Federation of the Associations of Dietitians (EFAD) conference is approaching and the publishing team of Gut Microbiota for Health is very pleased to be taking part with both a session and a booth! On September 29th and 30th, 2017 the World Trade Centre in Rotterdam (the Netherlands) will host the 10th conference of EFAD, a federation of…

GMFH Editing Team
GMFH Editing Team

The 10th European Federation of the Associations of Dietitians (EFAD) conference is approaching and the publishing team of Gut Microbiota for Health is very pleased to be taking part with both a session and a booth! On September 29th and 30th, 2017 the World Trade Centre in Rotterdam (the Netherlands) will host the 10th conference of EFAD, a federation of…

GMFH Editing Team
GMFH Editing Team

The International Scientific Association for Probiotics and Prebiotics (ISAPP) held its annual meeting in Chicago at the end of June, 2017. This meeting featured the latest science in the probiotic and prebiotic fields, consistent with ISAPP’s mission to advance the science of probiotics and prebiotics. Topics of discussion ranged from "How to define useful biomarkers for health?" to an update…

Mary Ellen Sanders
Mary Ellen Sanders is a consultant in the area of probiotic microbiology, with special expertise on paths to scientific substantiation of probiotic product label claims. Dr. Sanders served as the founding president of the International Scientific Association for Probiotics and Prebiotics (ISAPP) and is currently the organization’s Director of Scientific Affairs/ Executive Officer. This international, non-profit association of academic and industrial scientists is dedicated to advancing the science of probiotics and prebiotics (www.isapp.net). Through numerous written, oral and video pieces, including a website, www.usprobiotics.org, she strives to provide objective, evidence-based information on probiotics for consumers and professionals. Key activities include: Panels to determine GRAS status of probiotic strains ; member of the American Gastroenterological Association Scientific Advisory Board for AGA Center for Gut Microbiome Research and Education ; World Gastroenterology Organisation Committee preparing practice guidelines for the use of probiotics and prebiotics for GI indications (2008, 2011, 2014) ; working group convened by the FAO/WHO that developed guidelines for probiotics (2002).

The International Scientific Association for Probiotics and Prebiotics (ISAPP) held its annual meeting in Chicago at the end of June, 2017. This meeting featured the latest science in the probiotic and prebiotic fields, consistent with ISAPP’s mission to advance the science of probiotics and prebiotics. Topics of discussion ranged from "How to define useful biomarkers for health?" to an update…

Mary Ellen Sanders
Mary Ellen Sanders is a consultant in the area of probiotic microbiology, with special expertise on paths to scientific substantiation of probiotic product label claims. Dr. Sanders served as the founding president of the International Scientific Association for Probiotics and Prebiotics (ISAPP) and is currently the organization’s Director of Scientific Affairs/ Executive Officer. This international, non-profit association of academic and industrial scientists is dedicated to advancing the science of probiotics and prebiotics (www.isapp.net). Through numerous written, oral and video pieces, including a website, www.usprobiotics.org, she strives to provide objective, evidence-based information on probiotics for consumers and professionals. Key activities include: Panels to determine GRAS status of probiotic strains ; member of the American Gastroenterological Association Scientific Advisory Board for AGA Center for Gut Microbiome Research and Education ; World Gastroenterology Organisation Committee preparing practice guidelines for the use of probiotics and prebiotics for GI indications (2008, 2011, 2014) ; working group convened by the FAO/WHO that developed guidelines for probiotics (2002).